AgoneX Biopharmaceuticals
AgoneX Biopharmaceuticals (formerly BioHealthonomics) is a clinical stage biopharmaceutical company developing AGX-201, a histamine receptor modulator for migraine prevention.
Founded
2011AgoneX Biopharmaceuticals (formerly BioHealthonomics) is a clinical stage biopharmaceutical company developing AGX-201, a histamine receptor modulator for migraine prevention.
The company's stated differentiation is mechanistic: its pipeline describes AGX-201 as a subcutaneous histamine receptor modulator acting upstream of mast-cell degranulation, and contrasts this with CGRP receptor antagonists that the company says work downstream, citing an approximately 50 percent patient response rate for the CGRP class. Company filings describe three issued U.S. patents and one issued Japanese patent on the platform, and a Phase II registration (NCT02021474) exists for the migraine indication.
The team roster lists headache-specialist clinicians and advisers drawn from Stanford, Thomas Jefferson University, and the Medical College of Wisconsin, including two company-affiliated co-founders. The 2017 offering page's forward-looking superiority claim about safety, efficacy, and cost versus CGRP products is company marketing and not an independently measured comparison; no head-to-head trial result exists in the sources assembled this run.
Source: agonexbio.com
AgoneX Biopharmaceuticals is a clinical-stage developer with no marketed product, so its business development motion is direct relationship-based outreach: the company's pipeline page directs commercial inquiries to a dedicated email address (bd@agonexbio.com) and general contact is handled through info@agonexbio.com and the site's contact page. No pricing page, reseller channel, or marketplace listing exists in the sources assembled this run, which is consistent with a pre-commercial prescription-drug developer rather than evidence about sales staffing.
The migraine market context AgoneX cites on its own site comes from published figures: the Migraine Research Foundation places migraine prevalence at about 39 million people in the U.S. and 1 billion worldwide, and the company quotes J.P. Morgan Research estimating the migraine product market will grow to $10 billion in coming years. Peer-reviewed 2024 reviews of the migraine pipeline still list AGX-201 among preventive candidates, with its Phase II trial (NCT02021474) enrolled in subjects requiring prophylactic treatment.
Strengths: the company holds patent protection it reports as three issued U.S. patents and one issued Japanese patent, a registered Phase II trial (NCT02021474) for AGX-201 in migraine prophylaxis, and a leadership and advisory roster drawn from academic headache centers including Stanford and Thomas Jefferson University.
The company's visible public-channel footprint comes from its 2017 equity crowdfunding campaign on StartEngine (a $50-per-share Reg CF offering that closed February 8, 2018) and from lobbying registrations covering 2015-2019; an ad-library-style paid-marketing check for agonexbio.com and biohealthonomics.com was not resolvable this run, so paid-channel claims stay unwritten.
Source: agonexbio.com
A drug-tracking service listed the AGX-201 program as inactive with a July 2022 update timestamp, while the company's own site remains current and markets the same program, so forward outlook rests on whether the Phase II program resumes. The company's longer-term plan names Alzheimer's disease, Parkinson's disease, multiple sclerosis, chronic traumatic encephalopathy, and amyotrophic lateral sclerosis as follow-on indications.
Source: tandfonline.com
Weaknesses: the company operates with a small workforce (LinkedIn size band 2-10 employees), raised modest capital through retail crowdfunding channels ($35,800 on StartEngine in 2018), and has no revenue on SEC filings; its most recent annual filing on EDGAR covers fiscal year 2019.
Opportunities: the company names five additional neurological indications for its platform after migraine, and its own site cites J.P. Morgan Research estimating a $10 billion migraine product market in coming years.
Threats: the CGRP preventive class AGX-201 would compete against is already FDA-approved and marketed by large manufacturers, and a drug-tracking service listed the AGX-201 program as inactive with a July 2022 timestamp, so funding and trial resumption are the near-term risks; the company's superiority claims versus CGRP products are its own marketing, not measured results.
Source: agonexbio.com